Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche par promoteur : Amgen
Homme Max 99 ans
Amgen, Inc
MAJ Il y a 4 ans
An international study to Compare the Efficacy and Safety of Romosozumab With Placebo in Men With Osteoporosis
To evaluate the effect of treatment with romosozumab for 12 months compared with placebo on percent changes in bone mineral density (BMD) at the lumbar spine as assessed by dual energy x ray absorptio...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme Max 99 ans
Amgen, Inc
MAJ Il y a 4 ans
Study to Assess the Efficacy and Safety of Romosozumab Treatment in Postmenopausal Women With Osteoporosis
For the 12-month double-blind placebo-controlled study period: To assess the effect of romosozumab treatment for 12 months compared with placebo on the subject incidence of new vertebral fracture ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme
Entre 18 ans
et 99 ans
Amgen
MAJ Il y a 4 ans
Amgen 20060447 : Essai de phase 1-2 randomisé, en double aveugle, évaluant la tolérance puis l'efficacité du panitumumab associé ou non à de l'AMG 102 ou à de l'AMG 479, chez des patients ayant un cancer colorectal métastatique, non muté pour le gène KRAS. [Informations issues du site clinicaltrials.gov et traduites par l'INCa] [essai clos aux inclusions]
A randomized, phase 1b/2 trial of AMG 102 or AMG 479 in combination with panitumumab versus panitumumab alone in subject with wild-type KRAS metastatic colorectal cancer,
Pays
France
Organes
Côlon ou Rectum (colorectal)
Spécialités
Thérapies Ciblées
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Amgen, Inc
MAJ Il y a 4 ans
A Study of the Effects of AMG 334 to Prevent Migraine Headaches Estudio sobre la Eficacia de AMG 334 en Prevenir Migrañas
To evaluate the effect of AMG 334 compared to placebo on the change from baseline in monthly migraine days, in subjects with episodic migraine Evaluar el efecto de AMG 334 en comparación con pla...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Amgen, Inc
MAJ Il y a 4 ans
The trial is designed to determine the safety and efficacy of ABP 501 compared with Adalimumab in subjects with moderate to severe plaque psorasis
The primary objective for this study is to evaluate the efficacy of ABP 501 in subjects with moderate to severe plaque psoriasis, as measured by the PASI percent improvement from baseline, compared wi...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Amgen, Inc
MAJ Il y a 4 ans
A study assessing if long-term use of evolocumab will be safe, well tolerated, and whether it causes any side effects
To describe the safety and tolerability of long-term administration of evolocumab.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Amgen, Inc
MAJ Il y a 4 ans
A Study to Test the Effect and Safety of Brodalumab Compared With Placebo and Ustekinumab and the Results of Changing Strength or Frequency of Brodalumab in People with Moderate to Severe Plaque Psoriasis: AMAGINE-3 Μια μελέτη για την εκτίμηση της αποτελεσματικότητας και της ασφάλειας με brodalumab έναντι εικονικού φαρμάκου και ustekinumab και τα αποτελέσματα and the Results of Changing Strength or Frequency of Brodalumab σε ασθενείς με μέτρια έως σοβαρή ψωρίαση κατά πλάκας: AMAGINE-3
Primary Placebo-family Objectives Compared with placebo: • To evaluate the efficacy of brodalumab (210 mg every 2 weeks [Q2W]; and 140 mg Q2W) in subjects with moderate to severe plaque psoriasis, ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Amgen, Inc
MAJ Il y a 4 ans
A single-dose study to assess the safety and the manner in which the body metabolizes (breaks down) and gets rid of cinacalcet HCl, specifically in children with kidney failure who are being treated with dialysis
• To evaluate the safety and tolerability of cinacalcet HCl after single administration to pediatric patients aged 28 days to < 6 years with CKD receiving dialysis
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Amgen, Inc
MAJ Il y a 4 ans
An Open-Label, Multi-Center, Phase 2 Safety and Efficacy Study of Denosumab (AMG 162) in Subjects with Recurrent or Unresectable Giant Cell Tumor (GCT) of Bone
Primary Objectives: To evaluate response to treatment of denosumab in subjects with recurrent or unresectable GCT. Response is defined as: • elimination of giant cells, or doubling of the percentage ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Amgen, Inc
MAJ Il y a 4 ans
Study to assess the tolerability and efficacy of AMG 145 co-administered with statins in patients with hypercholesterolemia
To evaluate the effect of 12 weeks of subcutaneous (SC) AMG 145 every 2 weeks (Q2W) or every-4-weeks (Q4W), compared with placebo, on percent change from baseline in low-density lipoprotein cholestero...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Précédent
12
13
14
15
16
17
18
19
20
21
Suivant